- Home
- OPEN vs SNDX Comparison
OPEN vs SNDX Comparison
Compare OPEN & SNDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OPEN
- SNDX
- Stock Information
- Founded
- OPEN 2014
- SNDX 2005
- Country
- OPEN United States
- SNDX United States
- Employees
- OPEN N/A
- SNDX N/A
- Industry
- OPEN Real Estate
- SNDX Biotechnology: Pharmaceutical Preparations
- Sector
- OPEN Finance
- SNDX Health Care
- Exchange
- OPEN Nasdaq
- SNDX Nasdaq
- Market Cap
- OPEN 1.1B
- SNDX 1.1B
- IPO Year
- OPEN N/A
- SNDX 2016
- Fundamental
- Price
- OPEN $1.38
- SNDX $12.80
- Analyst Decision
- OPEN Hold
- SNDX Strong Buy
- Analyst Count
- OPEN 4
- SNDX 10
- Target Price
- OPEN $2.23
- SNDX $36.20
- AVG Volume (30 Days)
- OPEN 34.2M
- SNDX 2.7M
- Earning Date
- OPEN 02-13-2025
- SNDX 02-25-2025
- Dividend Yield
- OPEN N/A
- SNDX N/A
- EPS Growth
- OPEN N/A
- SNDX N/A
- EPS
- OPEN N/A
- SNDX N/A
- Revenue
- OPEN $4,939,000,000.00
- SNDX $16,000,000.00
- Revenue This Year
- OPEN N/A
- SNDX N/A
- Revenue Next Year
- OPEN $20.86
- SNDX N/A
- P/E Ratio
- OPEN N/A
- SNDX N/A
- Revenue Growth
- OPEN N/A
- SNDX N/A
- 52 Week Low
- OPEN $1.33
- SNDX $12.40
- 52 Week High
- OPEN $3.78
- SNDX $25.34
- Technical
- Relative Strength Index (RSI)
- OPEN 29.12
- SNDX 36.65
- Support Level
- OPEN $1.60
- SNDX $12.40
- Resistance Level
- OPEN $1.83
- SNDX $14.65
- Average True Range (ATR)
- OPEN 0.10
- SNDX 0.61
- MACD
- OPEN -0.02
- SNDX 0.14
- Stochastic Oscillator
- OPEN 10.00
- SNDX 17.78
About OPEN Opendoor Technologies Inc
Opendoor Technologies Inc is a digital platform for residential real estate. This platform enables customers to buy and sell houses online. It generates revenue through home sales, along with other revenue from real estate services.
About SNDX Syndax Pharmaceuticals Inc.
Syndax Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing a pipeline of combination therapies in multiple cancer indications. The company's product candidates are entinostat which has direct effects on both cancer cells and immune regulatory cells, SNDX-6352 and SNDX-6352, an anti-CSF-1R monoclonal antibody, to enhance the body's immune response on tumors that have shown sensitivity to immunotherapy. Business activity of the group is primarily functioned through the region of United States.